1 Recommendations

1 Recommendations

1.1

The case for adopting the XprESS multi‑sinus dilation system for treating uncomplicated chronic sinusitis after medical treatment has failed is supported by the evidence. Treatment with XprESS leads to a rapid and sustained improvement in chronic symptoms, fewer acute episodes and improved quality of life which is comparable to functional endoscopic sinus surgery (FESS).

1.2

XprESS should be considered in patients with uncomplicated chronic sinusitis who do not have severe nasal polyposis. In these patients, XprESS works as well as FESS, is associated with faster recovery times, and can more often be done under local anaesthesia.

1.3

Cost modelling indicates that XprESS is cost saving compared with FESS when treatment is done using local anaesthetic in an outpatient setting. The estimated saving per patient is £152, assuming that 80% of treatments are done this way, FESS takes 60 minutes and the device cost for XprESS is £820. By adopting this technology, the NHS in England may save around £7.4 million a year by 2020. Estimated savings are mainly achieved through the shift of treatment from operating theatre to outpatient setting.